Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF)

• Status: Completed
• Trial end date: 1991-06-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine the benefits and risks of oral anticoagulant therapy in reducing embolic stroke and systemic emboli in patients with atrial fibrillation without rheumatic heart disease.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Massachusetts General Hospital
• Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
• Treatments: Warfarin

Criteria

Men and women, 18 years of age or older, with non-rheumatic atrial fibrillation.